RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0032-1327286
Leichte kognitive Störung
Publikationsverlauf
Publikationsdatum:
30. November 2012 (online)
Patienten mit kognitiven Beeinträchtigungen im Alter, welche nicht an einer Demenz leiden, jedoch die diagnostischen Kriterien einer (amnestischen) MCI erfüllen, können zur Beantwortung der Frage nach ihrer individuellen Prognose im Hinblick auf das Risiko, zu einer (Alzheimer-)Demenz zu konvertieren, in Gedächtnissprechstunden vorgestellt werden. Dort wird mit Bestimmung der Biomarker der neuronalen Degeneration und der Beta-Amyloid-Akkumulation ggf. eine Aussage zur individuellen Prognose des Patienten möglich sein. Dabei ist jedoch unbedingt zu berücksichtigen, dass es bisher keine medikamentöse Therapie gibt, die zur Behandlung des MCI zugelassen ist, da eine positive Beeinflussung des Verlaufs mit den bisherigen Präparaten in Studien nicht nachzuweisen war. Insbesondere wird von einer Verordnung von Antidementiva aus der Gruppe der Azetylcholinesterase-Inhibitoren vor der Konversion zur Demenz im Allgemeinen abgeraten. Leitliniengemäß wird bei Feststellung der Konversion resp. Diagnose einer leichten und mittelschweren AD eine medikamentöse Therapie mit einem Azetylcholinesterase-Inhibitor empfohlen.
Vom National Institute on Aging und der Amerikanischen Alzheimer-Gesellschaft wurde im April 2011 nach 27 Jahren die Alzheimererkrankung neu definiert. Ein Schwerpunkt dieser neuen Diagnosekriterien ist der Versuch, unter Zuhilfenahme der Erkenntnisse über die Biomarker MCI-Patienten mit einer Alzheimererkrankung, welche letztlich dann auch zu einer Alzheimerdemenz konvertieren werden, von jenen abzugrenzen, für die keine Alzheimererkrankung als Ursache der MCI vorliegt oder die auch als gutartig zu bezeichnen sind.
-
Literatur
- 1 Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991; 41: 1006-1009
- 2 Flicker C, Ferris SH, Reisberg B. A longitudinal study of cognitive function in elderly persons with subjective memory complaints. J Am Geriatr Soc 1993; 41: 1029-1032
- 3 Smith GE, Petersen RC, Ivnik R et al. Subjective memory complaints, psychological distress, and longitudinal change in objective memory performance. Psychol Aging 1996; 11: 272-279
- 4 Petersen RC, Smith GE, Warning SC et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
- 5 Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 2011; 7: 257-262
- 6 Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s disease. Alzheimer’s Dement 2011; 7: 270-279
- 7 McKhann GM, Knopmann DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s Dement 2011; 7: 263-269
- 8 Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194
- 9 Perneczky R, Sorg C, Hartmann J et al. Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry 2006; 21: 158-162
- 10 Giovannetti T, Bettcher BM, Brennan L et al. Characterization of everyday functioning in mild cognitive impairment: a direct assessment approach. Dement Geriatr Cogn Disord 2008; 25: 359-365
- 11 Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007; 27: 22-31
- 12 Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr 2008; 13: 45-53
- 13 Abdulrab K, Heun R. Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatry 2008; 23: 321-330
- 14 Lopez OL, Jagust WJ, DeKosky ST et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 2003; 60: 1385-1389
- 15 Luck T, Riedel-Heller SG, Kaduszkiewicz H et al. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on aging, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord 2007; 24: 307-316
- 16 Busse A, Hensel A, Gühne U et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176-2185
- 17 Bickel H, Mösch E, Seigerschmidt E. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dement Geriatr Cogn Disord 2006; 21: 242-250
- 18 Lyketsos CG, Lopez O, Jones B et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. J Am Med Assoc 2002; 288: 1475-1483
- 19 Geda YE, Roberts RO, Knopman DS et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 2008; 65: 1193-1198
- 20 Morawetz C, Ackermann C, Wormstall H. Psychosoziale Aspekte leichter kognitiver Beeinträchtigungen im Alter. Z Gerontopsychol und -psychiatrie 2001; 14: 137-142
- 21 Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr 2008; 13: 45-53
- 22 Schmidtke K, Hermeneit S. High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients. Int Psychogeriatr 2008; 20: 96-108
- 23 Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388
- 24 Dickerson BC, Sperling RA, Hyman BT et al. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 1443-1450
- 25 Bertram L, Lill C, Tanzi R. The genetics of Alzheimer disease: back to the future. Neuron 2010; 21: 270-281
- 26 http://www.demenz-leitlinie.de/
- 27 Klöppel S, Stonnington CM, Chu C et al. Automatic classification of MR scans in Alzheimer’s disease. Brain 2008; 131: 681-689
- 28 Teipel SJ, Born C, Ewers M et al. Multivariate deformatio-based analysis of brain atrophy to predict Alzheimer’s disease in mild cognitive impairment. Neuroimage 2007; 38: 13-24
- 29 Fleisher MD, Sun S, Taylor C et al. Volumetric MRI vs. clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008; 70: 191-199
- 30 Mc Evoy LK, Fennema-Noestine C, Rodey JC et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009; 25: 195-205
- 31 Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
- 32 Landau SM, Harvey D, Madison CM et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-238
- 33 Quigley H, Colloby SJ, O’Brien JT. PET-Imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 2011; 26: 991-999
- 34 Minoshima S, Frey KA, Koeppe RA et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nuclear Med 1995; 36: 1238-1248
- 35 Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746
- 36 Petersen RC, Thomas RG, Grundmann M et al. Vitamin E and donezepil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388
- 37 Winblad B, Gauthier S, Scinto L et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024-2035 (Erratum Neurology 2010; 75: 1485)
- 38 Feldman HH, Ferris S, Winblad B et al. Effect of rivastgmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2001; 6: 501-512 (Erratum Lancet Neurol 2007; 6: 849)
- 39 Knopman DS. Current treatment of mild cognitive impairment and Alzheimer’s disease. Curr Neurol Neurosci Rep 2006; 6: 365-371
- 40 Schneider LS, Insel PS, Weiner MW. Alzheimer’s Disease neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Neurol 2011; 68: 58-66
- 41 Devanand DP, Pelton GH, Marston K et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 2003; 18: 123-130
- 42 http://www.depression.versorgungsleitlinien.de/
- 43 Banerjee S, Heller J, Dewey M et al. Sertralin or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378: 403-411
- 44 Jean L et al. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010; 18: 281-296
- 45 Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66: 216-225
- 46 Sofi F, Valecchi D, Bacci D et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. Intern Med 2011; 269: 107-117